Clinical trials: Schizophrenia and Disorders With Psychotic Feature
Schizophrenia
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
A multicenter, randomized, double-blind, placebo-controlled, dose-increasing phase Ib/II clinical trial to evaluate the safety, tolerance and pharmacokinetic characteristics of JX11502MA capsules administered multiple times in…
- Trial name
- NCT06356389
- Testing
- JX11502MA
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness
Recovery-oriented care is an imperative for the VA, particularly in mental health programming for Veterans with serious mental illness (SMI).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- CDST (NCT04324944)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Mental Disorders
Effects of Delta-9-THC and Iomazenil in Healthy Humans
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG).
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Trial name
- NCT00982982
- Testing
- THC and Iomazenil
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Psychotic Disorders
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
- Trial name
- NCT00309413
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Schizophrenia, Schizoaffective Disorder
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
- Trial name
- NCT01878513
- Testing
- risperidone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Northwell Health
Psychosis, Schizophrenia Disorder
Cognitive Strategies in Early Psychosis 2
The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last…
- Conditions
- Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- COSTEP 2 (NCT07263022)
- Testing
- Modafinil, D-serine solution
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Social Cognition in Longstanding Psychosis
In the current study, the investigators propose to measure the five domains of social cognition identified by the National Institute of Mental Health (NIMH) as relevant to individuals with psychosis (i.e., theory of mind…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01624831
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features
Transition Care for FEP
This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care.
- Conditions
- Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features
- Trial name
- TCT FEP (NCT07713849)
- Testing
- Transition Care Team
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Chicago
Schizophrenia
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia.
- Trial name
- NCT00963924
- Testing
- D-cycloserine, Cognitive Remediation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2
Nicotine dependence is very common among individuals with schizophrenia and schizoaffective disorder. Cotinine is a chemical that is made by the body from nicotine.
- Trial name
- NCT00135772
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia and Disorders With Psychotic Features
Specialized Treatment Early in Psychosis (STEP)
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis.
- Trial name
- STEP (NCT00309452)
- Testing
- Cognitive Behavioral Group Therapy, Cognitive remediation, Medications
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Yale University
Schizophrenia and Disorders With Psychotic Features, Psychotic Episode
Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)
The current investigation aims to compare two group intervention in patients with a first episode of psychosis, that is, people who have suffered their first psychotic episode within 5 years prior to their inclusion in the study.
- Trial name
- AGES-Mind (NCT03309475)
- Testing
- SocialMIND, Psychoeducational multicomponent intervention, Psychosocial treatment
- Where
- Spain
- Volunteers
- 59 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Schizophrenia, Schizoaffective Disorder
Academic-Community EPINET (AC-EPINET)
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features
- Trial name
- AC-EPINET (NCT04497857)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- NCT01731119
- Testing
- Latuda©
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Schizophrenia and Disorders With Psychotic Features
Social Skills Training in Refractory Schizophrenia
Objective Primary: To evaluate the efficacy of social skills training in reducing negative symptoms in patients with refractory schizophrenia, in comparison with control (befriending group).
- Trial name
- SST (NCT00791882)
- Testing
- Social Skills Training
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- University of Sao Paulo
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers.
- Trial name
- NCT00136760
- Testing
- Bupropion, non-contingent reinforcement plus bupropion
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Brown University